This is a Randomized Study of Early Involvement of Palliative Care Along Side Standard Treatment Versus Standard Treatment Alone in Newly Diagnosed Patients With Advanced or Metastatic Soft Tissue Sarcoma (SARQUALITY) (NCT06805669)
Integrating Early Palliative Care in Advanced SARcoma Patients for Enhanced QUALITY of Life: the SARQUALITY Study
🩺 Plain-English Summary (8th-Grade Level)
The goal of this study is to learn whether early referral to palliative care improves quality of life for patients with advanced sarcoma. Participants enrolled in this study will complete quality of life questionnaires before starting their treatment, and every 6 weeks for 24 weeks.
Who can join: Review the eligibility criteria below.
Location: Mount Sinai Hospital — Toronto, Ontario
Age range: 18 Years
🧪 Interventions in This Study
- Early referral to palliative care (OTHER)
- Standard Treatment (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Mount Sinai Hospital — Toronto, Ontario
📞 Contact the Study Coordinator
Phone: (416) 586-8440
Email: Oncology.Research@sinaihealth.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Sarcoma
- Hyperbaric Oxygen Therapy for Soft Tissue Sarcoma Pilot Study — Durham, North Carolina
- Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma — Milwaukee, Wisconsin
- Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor — New York, New York
- Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma — Houston, Texas
- Registry of Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet® — Philadelphia, Pennsylvania
- A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma — New York, New York
Explore by condition: All Sarcoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.